Letter abstract


Nature Medicine 15, 802 - 807 (2009)
Published online: 7 June 2009 | doi:10.1038/nm.1976

Hematopoietic colony–stimulating factors mediate tumor-nerve interactions and bone cancer pain

Matthias Schweizerhof1, Sebastian Stösser1,6, Martina Kurejova1,6, Christian Njoo1,6, Vijayan Gangadharan1, Nitin Agarwal1, Martin Schmelz2, Kiran Kumar Bali1, Christoph W Michalski1,3,7, Stefan Brugger1,7, Anthony Dickenson4, Donald A Simone5 & Rohini Kuner1

Top

Pain is one of the most severe and debilitating symptoms associated with several forms of cancer1, 2. Various types of carcinomas and sarcomas metastasize to skeletal bones and cause spontaneous bone pain and hyperalgesia, which is accompanied by bone degradation and remodeling of peripheral nerves2. Despite recent advances, the molecular mechanisms underlying the development and maintenance of cancer-evoked pain are not well understood2. Several types of non-hematopoietic tumors secrete hematopoietic colony-stimulating factors that act on myeloid cells3 and tumor cells4. Here we report that receptors and signaling mediators of granulocyte- and granulocyte-macrophage colony-stimulating factors (G-CSF and GM-CSF)3 are also functionally expressed on sensory nerves. GM-CSF sensitized nerves to mechanical stimuli in vitro and in vivo, potentiated CGRP release and caused sprouting of sensory nerve endings in the skin. Interruption of G-CSF and GM-CSF signaling in vivo led to reduced tumor growth and nerve remodeling, and abrogated bone cancer pain. The key significance of GM-CSF signaling in sensory neurons was revealed by an attenuation of tumor-evoked pain following a sensory nerve–specific knockdown of GM-CSF receptors. These results show that G-CSF and GM-CSF are important in tumor-nerve interactions and suggest that their receptors on primary afferent nerve fibers constitute potential therapeutic targets in cancer pain.

Top
  1. Pharmacology Institute, University of Heidelberg, Heidelberg, Germany.
  2. Department of Anesthesiology and Intensive Care Medicine, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  3. Department of General Surgery, University of Heidelberg, Heidelberg, Germany.
  4. Department of Pharmacology, University College London, London, UK.
  5. Department of Diagnostic & Biological Sciences, University of Minnesota, School of Dentistry, Minneapolis, Minnesota, USA.
  6. These authors contributed equally to this work.
  7. Present addresses: Surgery Clinic, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany (C.W.M.); Anesthesiology and Intensive Medicine, University Clinic of Basel, Basel, Switzerland (S.B.).

Correspondence to: Rohini Kuner1 e-mail: rohini.kuner@pharma.uni-heidelberg.de



MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Choosing between GVHD and delayed engraftment

Nature Medicine News and Views (01 Apr 2009)


Extra navigation

Subscribe to Nature Medicine

Subscribe

Open Innovation Challenges

naturejobs

ADVERTISEMENT